Novartis to Present New Dermatology Data at AAD 2026

Novartis is preparing to share new clinical findings at the American Academy of Dermatology (AAD) Annual Meeting 2026, focusing on treatments for chronic skin conditions and how patients respond over time.

The company will present more than 20 abstracts from its immunology portfolio, highlighting progress in treating diseases such as chronic spontaneous urticaria (CSU), hidradenitis suppurativa (HS), and psoriasis treatment. The data reflects Novartis’ continued efforts to improve care for people living with long-term inflammatory skin disorders.

One of the key highlights includes new data on remibrutinib, which shows patients with CSU experienced relief from itching and hives as early as the first week of treatment. This early response could make a meaningful difference for patients who struggle with persistent symptoms.

Novartis will also share updated findings on Cosentyx (secukinumab), focusing on its ability to help prevent flare-ups in patients with hidradenitis suppurativa. In addition, long-term data from clinical trials—spanning up to five years—will be presented, showing sustained effectiveness in managing both HS and psoriasis.

Also Read: Pfizer-Valneva Lyme Vaccine Shows Strong Phase 3 Efficacy

According to the company, these results demonstrate not only the effectiveness of its treatments but also their potential to deliver lasting benefits. The presentations are expected to provide healthcare professionals with deeper insights into how these therapies perform in real-world settings.

Novartis emphasized that its goal is to develop treatments that offer both fast symptom relief and long-term disease control. With a growing pipeline in immunology, the company continues to focus on improving patient outcomes and quality of life for those dealing with chronic skin diseases.

The upcoming AAD meeting will serve as an important platform for sharing these developments with the global dermatology community.